Genetic Signatures’ CEO, Allison Rossiter, brings a distinguished career in healthcare. With a proven track record at Roche Diagnostics, she navigated complex strategic challenges to achieve notable success. Ms Rossiter’s vision and leadership will be invaluable to Genetic Signatures as we enter our next phase of growth. She is warmly welcomed by the team! Allison…

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia. Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior…

Genetic Signatures shares a bittersweet moment as we bid farewell to Dr. John Melki, who has announced his decision to step down as CEO and Director after an illustrious 21 years of leadership. John possesses an extraordinary blend of qualities and skills that have not only inspired, but also motivated and guided our team through a…

A recent article published via Sharecafe discusses Genetic Signatures’ new syndromic EasyScreen™ targets for use in EU and US Markets. To read more Click link

Genetic Signatures Annual Report 2020 released. Click link for more information.

Genetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar to be held at 12.30 pm AEST on Friday, 28 August 2020. The webinar is free to join and participants are required to register in advance via the following link: https://us02web.zoom.us/webinar/register/WN_Mjb04hQtSY-nlSbLqWlpSw

Genetic Signatures latest Investor Presentation released. Click link for more information.

Genetic Signatures latest Investor Presentation released. Click link for more information.